About: Antibodies to watch in 2020

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibodies to watch in 2020 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibodies to watch in 2020
Creator	Reichert, Janice Kaplon, Hélène Muralidharan, Mrinalini Schneider, Zita
Source	PMC
abstract	This 2020 installment of the annual ‘Antibodies to Watch’ series documents the antibody therapeutics approved in 2019 and in regulatory review in the United States or European Union, as well as those in late-stage clinical studies, as of November 2019. At this time, a total of 5 novel antibody therapeutics (romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, and crizanlizumab) had been granted a first approval in either the US or EU, and marketing applications for 13 novel antibody therapeutics (eptinezumab, teprotumumab, enfortumab vedotin, isatuximab, [fam-]trastuzumab deruxtecan, inebilizumab, leronlimab, sacituzumab govitecan, satralizumab, narsoplimab, tafasitamab, REGNEB3 and naxituximab) were undergoing review in these regions, which represent the major markets for antibody therapeutics. Also as of November 2019, 79 novel antibodies were undergoing evaluation in late-stage clinical studies. Of the 79 antibodies, 39 were undergoing evaluation in late-stage studies for non-cancer indications, with 2 of these (ublituximab, pamrevlumab) also in late-stage studies for cancer indications. Companies developing 7 (tanezumab, aducanumab, evinacumab, etrolizumab, sutimlimab, anifrolumab, and teplizumab) of the 39 drugs have indicated that they may submit a marketing application in either the US or EU in 2020. Of the 79 antibodies in late-stage studies, 40 were undergoing evaluation as treatments for cancer, and potentially 9 of these (belantamab mafodotin, oportuzumab monatox, margetuximab, dostarlimab, spartalizumab, 131I-omburtamab, loncastuximab tesirine, balstilimab, and zalifrelimab) may enter regulatory review in late 2019 or in 2020. Overall, the biopharmaceutical industry’s clinical pipeline of antibody therapeutics is robust, and should provide a continuous supply of innovative products for patients in the future. Note on key updates through December 18, 2019: 1) the US Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev) on December 18, 2019, bringing the total number of novel antibody therapeutics granted a first approval in either the US or EU during 2019 to 6; 2) the European Commission approved romosozumab on December 9, 2019; 3) the European Medicines Agency issued a positive opinion for brolucizumab; 4) Sesen Bio initiated a rolling biologics license application (BLA) on December 6, 2019; 5) GlaxoSmithKline submitted a BLA for belantamab mafodotin; and 6) the status of the Phase 3 study (NCT04128696) of GSK3359609, a humanized IgG4 anti-ICOS antibody, in patients with head and neck squamous cell carcinoma was updated to recruiting from not yet recruiting.
has issue date	2019-12-26(xsd:dateTime)
bibo:doi	10.1080/19420862.2019.1703531
bibo:pmid	31847708
has license	cc-by-nc
sha1sum (hex)	106b3a01f9a2d16d46bb32b692552e8ede48701f
schema:url	https://doi.org/10.1080/19420862.2019.1703531
resource representing a document's title	Antibodies to watch in 2020
has PubMed Central identifier	PMC6973335
has PubMed identifier	31847708
schema:publication	MAbs
resource representing a document's body	covid:106b3a01f9a2d16d46bb32b692552e8ede48701f#body_text
is schema:about of	named entity 'KEY' named entity '131I-OMBURTAMAB' named entity 'STATUS' named entity 'ANIFROLUMAB' named entity 'REVIEW' named entity 'SUPPLY' named entity 'INDUSTRY' named entity 'DEVELOPING' named entity 'ROMOSOZUMAB' named entity 'DECEMBER' named entity 'POSITIVE' named entity 'PIPELINE' named entity 'APPROVAL' named entity 'ADUCANUMAB' named entity 'SUBMITTED' named entity 'INDICATIONS' named entity '131I' named entity 'risankizumab' named entity 'Phase 3 study' named entity 'brolucizumab' named entity 'antibody' named entity 'European Commission' named entity 'antibody' named entity 'ICOS' named entity 'margetuximab' named entity 'antibodies' named entity 'spartalizumab' named entity 'European Medicines Agency' named entity 'MorphoSys' named entity '8 letters' named entity 'DLBCL' named entity 'CHMP' named entity 'Phase 2' named entity 'caplacizumab' named entity 'teprotumumab' named entity 'antibody' named entity 'lupus nephritis' named entity 'IFN' named entity 'disability' named entity 'Psoriasis Area and Severity Index' named entity 'mCi' named entity 'placebo' named entity 'cystectomy' named entity 'placebo' named entity 'VEGFR-1' named entity 'antigens' named entity 'HER2' named entity 'HSCT' named entity 'lower back pain' named entity 'MAA' named entity 'GD2' named entity 'antibody' named entity 'Risankizumab' named entity 'primary endpoint' named entity 'ORR' named entity 'spartalizumab' named entity 'Breakthrough Therapy Designation' named entity 'lenalidomide' named entity 'biologics license application' named entity 'epitope' named entity 'gastroesophageal junction' named entity 'eye bulging' named entity 'Phase 2 trial' named entity 'placebo' named entity 'BLA' named entity 'BLA' named entity 'teprotumumab' named entity 'SKYRIZI' named entity 'T1D' named entity 'cytokine' named entity 'placebo' named entity 'chemotherapy agent' named entity 'Breakthrough Therapy designation' named entity 'AbbVie' named entity 'β7 subunit' named entity 'dose-escalation' named entity 'Phase 3 clinical trials' named entity 'capecitabine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software